New progress of drug therapy in advanced non-small cell lung cancer
HU Yi
TAO Hai-tao
Abstract：[ABSTRACT]Lung cancer is the leading cause of cancer mortality. Due to the progress in molecular target therapy, great progress has been achieved in advanced non-small cell lung cancer (NSCLC). Many treatments have been demonstrated to improve the objective remission rate, quality of life and even the progressive free survival and overall survival in translational researches. Traditional chemotherapy is very important for NSCLC patients, especially for those wild-type or unknown gene mutation patients;the progress in molecular target therapy just revolutionize the treatment of NSCLC and become the ifrst choice for those patients with gene sensitive mutation; the progresses of drugs which target speciifc checkpoint of immune system have led the immunotherapy to new heights, immunotherapy become the new choice for NSCLC. No matter chemotherapy, target therapy or immunotherapy, the treatments based on exact change of the molecular pathogenesis are the development direction of NSCLC.
Keywords：Non-small cell lung cancerChemotherapyMolecular target therapyImmunotherapy
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 329-333 )